Advances in T-Lymphokine-activated Killer Cell-originated Protein Kinase Research in Cancer Over the Past Thirty Years
T-cell infiltration, promoting immune evasion. Although numerous natural and synthetic inhibitors of TOPK have been identified, their clinical application remains at an early stage. Overall, current evidence presents TOPK as a promising biomarker and therapeutic target with broad relevance across diverse cancer types.
Authors
- Mee‐Hyun Lee (ORCID: https://orcid.org/0000-0002-1216-0218)
- Mengyu Zhao
- Ran Zhao
Institutions
- Dongshin University (KR)
- Zhengzhou University (CN)
- Henan Tianguan Group (China) (CN)
- China-US (Henan) Hormel Cancer Institute (CN)
Publication Details
- Journal
- Journal of Cancer Prevention
- Published
- 2026-03-31
- DOI
- https://doi.org/10.15430/jcp.25.055
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Natural Science Foundation of China
- Ministry of Education
- China Postdoctoral Science Foundation
- National Research Foundation of Korea
- Ministry of Education, India
- Science and Technology Department, Henan Province
- Ministry of Science and ICT, South Korea